Stocks
GlaxoSmithKline (GSK) ROE US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| ROE, % | ? | 21.5% | 141.1% | 29.0% | 18.8% | 35.0% | 24.8% | ||
| Changes by years, y/y, % | -7pp | +120pp | -112pp | -10pp | +16pp | +3.9% | |||
GlaxoSmithKline. ROE, %
GlaxoSmithKline. ROE, changes, pp
GlaxoSmithKline (GSK) ROE US GAAP (quarter values) |
||||||||
| FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| ROE, % | ? | 16.9% | 25.3% | 35.0% | 35.0% | 24.8% | 24.8% | |
| Changes by years, y/y, % | -5pp | +7pp | +16pp | +16pp | +8pp | |||
| Changes by quarters, q/q, % | 0pp | +8pp | +10pp | 0pp | -10pp | |||
